Search
About Us
Our goal at PhysioGenix is to become the world-leader in preclinical research services for studies focused on diabetes, cardiovascular disease and renal disease. Our extensive in-house capabilities combined with our world renowned expert consultants assist in providing the most comprehensive suite of solutions for all of your research needs.
Our highly skilled team has developed and delivered a wide-range of services for our valued customers. We pride ourselves in providing personalized services to a diverse range of clients, from the top pharmaceutical and biotechnology companies in the world, to exclusive, early-stage research companies. Our commitment is to work with our clients continuously in the development of customized research programs, and to carry out these projects with precision and accountability.
PhysioGenix is a proud member of AALAS (American Association for Laboratory Animal Science).
Brian D. Curry, Ph. D., MBA, President and Chief Executive Officer
As President and Chief Executive Officer, Dr. Curry sets PhysioGenix’s direction and corresponding implementation strategy to maximize value for all stakeholders. By building a positive culture, nimble team and managing PhysioGenix's finances, Dr. Curry has positioned PhysioGenix to be a leading provider of preclinical pharmacological services; these services help accelerate drug development in the diabetes, behavioral and cardiovascular fields. Dr. Curry currently serves on the Board of Directors for Fotodyne Incorporated. Preceding his role as President and CEO, Dr. Curry was PhysioGenix’s Chief Operating Officer where he was responsible for managing day-to-day activities and identifying innovative solutions to bring products to market. Prior to joining PhysioGenix, Dr. Curry was President of Functional Design for 10 years, which provided biomechanical design, testing and consulting to national and global companies. During this time, he brought products from concept sketches through manufacturing and product launch. Dr. Curry has also performed consulting with over 40 early-stage technology companies in product assessment, market forecasting and financing. He holds a Ph.D. in Cell Biology, Neurobiology and Anatomy and an M.S. in Pharmacology & Toxicology from the Medical College of Wisconsin, a Certificate in Finance from Keller Graduate School of Management, M.S. in Biological Sciences/Physiology from Western Michigan University and a B.S. in Physics from Michigan State University.